Why Is BPDCN Frequently Misdiagnosed? Common Mimics

If your Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) was initially brushed off as a stubborn rash, severe bruising, or a different blood disorder, you are not alone. BPDCN can be difficult to diagnose in its early stages. Many patients experience a period of trial-and-error treatments, such as topical steroid creams, before arriving at the correct diagnosis ^[1].

A key reason for this delay is that BPDCN is rare, with an incidence rate estimated at roughly 0.04 cases per 100,000 people ^[2]. Because it is so uncommon, many local dermatologists and primary care doctors may not have encountered it before. While BPDCN can involve the blood, bone marrow, and lymph nodes without any skin symptoms, the early signs are often found on the skin, where they can mimic common and benign (non-cancerous) conditions.

Benign Conditions Commonly Confused With BPDCN

Because BPDCN skin lesions can look incredibly varied—appearing as flat red spots (erythematous macules), raised purple bumps, or brown nodules—they are often initially mistaken for everyday skin issues ^[3][4]. Common early misdiagnoses include:

• Severe Bruising or Hematomas: The lesions can appear as purpura (purple spots caused by bleeding under the skin) or look exactly like a severe traumatic bruise that simply won’t heal ^[5].
• Inflammatory Skin Conditions: The redness and raised nature of some lesions can lead doctors to suspect eczema, psoriasis, or lupus.
• Unexplained Rashes: BPDCN can present as simple red spots that look like a generic allergic reaction or viral rash ^[3].

When these lesions are persistent, unexplained, rapidly changing, or do not respond to standard primary care treatments, it is a sign that deeper clinical assessment and a potential biopsy are needed ^[1]. Do not delay further medical evaluation by endlessly trying new topical treatments if your symptoms are worsening.

If you experience rapidly worsening lesions, significant bleeding, fever, severe fatigue, or other symptoms associated with low blood counts, seek prompt medical attention.

Confusion With Other Blood Cancers

Even when a doctor correctly suspects a blood cancer and performs a biopsy, BPDCN can still be misdiagnosed as a different, more common type of malignancy. Looking at the cells under a standard microscope (evaluating their morphology) is not enough to accurately identify BPDCN ^[6]. It frequently looks identical to other immature blood cancers in the skin ^[7].

BPDCN is commonly misdiagnosed as:

• Cutaneous T-Cell Lymphoma: A more common type of skin-based blood cancer ^[4].
• Acute Myeloid Leukemia (AML) and Leukemia Cutis: Leukemia cutis is the term used when leukemia cells infiltrate the skin. AML that presents as leukemia cutis can share similar features and even share certain cellular markers with BPDCN ^[7][8].
• Other Neoplasms: It can also be confused with myeloid sarcomas, B- or T-lymphoblastic leukemia, or NK-cell neoplasms.

The Challenge in the Pathology Lab

To definitively diagnose BPDCN, pathologists cannot just look at the shape of the cells; they must look for patterns of specific proteins on the cells using techniques called immunohistochemistry (using antibodies to stain proteins in tissue) and flow cytometry (measuring proteins on individual cells) ^[9].

A typical BPDCN case will often show a pattern that tests positive for markers like CD4, CD56, CD123, and TCL1 ^[9]. However, this is not a rigid requirement, and some markers can overlap with other cancers. For example, some BPDCN cells are negative for CD56, which can easily throw off the diagnosis unless the pathologist runs an expanded panel of tests, including markers like SOX4 ^[10]. Diagnosis relies on an integrated clinical and pathologic review, assessing the right markers while excluding markers that define other blood cancers.

Because the diagnostic criteria are complex and the disease is rare, confirming a BPDCN diagnosis generally requires the expertise of specialized dermatopathologists or hematopathologists at referral centers ^[6][11].